Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q81574484)
Watch
English
Minimizing infliximab toxicity in the treatment of inflammatory bowel disease
scientific article published on 01 July 2008
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
title
Minimizing infliximab toxicity in the treatment of inflammatory bowel disease
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
main subject
inflammatory bowel diseases
1 reference
based on heuristic
inferred from title
author
Mario Cottone
series ordinal
5
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
author name string
A Orlando
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
F Mocciaro
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
G Civitavecchia
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
D Scimeca
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
publication date
1 July 2008
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
published in
Digestive and Liver Disease
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
volume
40 Suppl 2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
page(s)
S236-46
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
cites work
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunogenicity of engineered antibodies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Review article: safety of infliximab in clinical trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Optimizing anti-TNF treatment in inflammatory bowel disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antibody responses in Crohn’s disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Autoimmunity and anti-TNF-alpha agents
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A lupus-like syndrome associated with infliximab therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety issues with biological therapies for inflammatory bowel disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab maintenance therapy for fistulizing Crohn's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab for induction and maintenance therapy for ulcerative colitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Reactivation of latent granulomatous infections by infliximab
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Perianal fistulae following infliximab treatment: clinical and endosonographic outcome.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Occult hepatitis B and infliximab-induced HBV reactivation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased risk of large-bowel cancer in Crohn's disease with colonic involvement
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Crohn's disease and cancer: a population-based cohort study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inflammatory bowel disease is not associated with an increased risk of lymphoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risk of haematopoietic cancer in patients with inflammatory bowel disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cancer risk in patients with inflammatory bowel disease: a population-based study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment with biologic therapies and the risk of cancer in patients with IBD.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased risk for demyelinating diseases in patients with inflammatory bowel disease.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety of tumour necrosis factor-alpha antagonists
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Problems encountered during anti-tumour necrosis factor therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival and causes of death in patients with inflammatory bowel disease: a population-based study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1590-8658%2808%2960532-0
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1590-8658(08)60532-0
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
PubMed publication ID
18598995
1 reference
stated in
Europe PubMed Central
PubMed publication ID
18598995
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18598995%20AND%20SRC:MED&resulttype=core&format=json
retrieved
10 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
